Kenvue Inc. $KVUE Shares Acquired by Avanza Fonder AB

Avanza Fonder AB grew its stake in shares of Kenvue Inc. (NYSE:KVUE) by 19.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 224,995 shares of the company’s stock after purchasing an additional 37,259 shares during the quarter. Avanza Fonder AB’s holdings in Kenvue were worth $3,652,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in KVUE. Vanguard Group Inc. grew its position in Kenvue by 1.8% in the 2nd quarter. Vanguard Group Inc. now owns 233,246,267 shares of the company’s stock valued at $4,881,844,000 after buying an additional 4,101,880 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Kenvue by 1.2% in the 2nd quarter. Geode Capital Management LLC now owns 49,001,887 shares of the company’s stock worth $1,021,267,000 after acquiring an additional 604,953 shares during the period. Independent Franchise Partners LLP lifted its stake in shares of Kenvue by 233.4% in the 2nd quarter. Independent Franchise Partners LLP now owns 31,265,574 shares of the company’s stock worth $654,388,000 after acquiring an additional 21,886,537 shares during the period. American Century Companies Inc. boosted its holdings in shares of Kenvue by 38.6% in the second quarter. American Century Companies Inc. now owns 30,265,020 shares of the company’s stock valued at $633,447,000 after acquiring an additional 8,436,166 shares in the last quarter. Finally, Norges Bank acquired a new position in shares of Kenvue during the second quarter valued at approximately $537,418,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Kenvue

In related news, Director Jeffrey C. Smith purchased 3,200,000 shares of Kenvue stock in a transaction on Friday, December 12th. The stock was bought at an average price of $17.37 per share, with a total value of $55,584,000.00. Following the completion of the transaction, the director directly owned 27,307,632 shares of the company’s stock, valued at approximately $474,333,567.84. This represents a 13.27% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 1.68% of the stock is owned by corporate insiders.

Kenvue Stock Down 0.1%

KVUE stock opened at $17.20 on Friday. The company has a 50 day moving average of $16.44 and a two-hundred day moving average of $18.73. The company has a market cap of $32.95 billion, a price-to-earnings ratio of 22.93 and a beta of 0.60. Kenvue Inc. has a 12-month low of $14.02 and a 12-month high of $25.17. The company has a quick ratio of 0.69, a current ratio of 0.98 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last issued its earnings results on Monday, November 3rd. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.01. Kenvue had a return on equity of 20.02% and a net margin of 9.55%.The company had revenue of $3.76 billion for the quarter, compared to analyst estimates of $3.83 billion. During the same period in the prior year, the firm posted $0.28 EPS. The business’s revenue was down 3.5% compared to the same quarter last year. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, equities analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, November 26th. Shareholders of record on Wednesday, November 12th were issued a dividend of $0.2075 per share. This represents a $0.83 annualized dividend and a yield of 4.8%. The ex-dividend date was Wednesday, November 12th. Kenvue’s dividend payout ratio (DPR) is 110.67%.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on KVUE. JPMorgan Chase & Co. decreased their target price on Kenvue from $24.00 to $21.00 and set an “overweight” rating for the company in a research note on Friday, October 10th. UBS Group cut their price target on shares of Kenvue from $23.00 to $17.00 and set a “neutral” rating for the company in a report on Wednesday, October 8th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Kenvue in a research note on Tuesday, October 14th. Citigroup dropped their target price on shares of Kenvue from $20.00 to $17.00 and set a “neutral” rating on the stock in a report on Thursday, October 9th. Finally, The Goldman Sachs Group reduced their target price on shares of Kenvue from $22.00 to $19.00 and set a “neutral” rating for the company in a report on Thursday, October 2nd. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and twelve have given a Hold rating to the stock. According to MarketBeat.com, Kenvue has a consensus rating of “Hold” and a consensus target price of $20.23.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.